AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05825482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.
Description: Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 2 randomization, the surgeons will be instructed to perform a partial mastectomy with selective margins shave margins using Savi Scout®. The lesion will be removed in the routine fashion. The Savi Scout® localizer will be utilized to determine selective shave margins by examining the same margins on the excised tissue specimen. The surgeon will obtain selective margins if the margin of the tissue specimen is within 1mm of invasive cancer and 2mm within DCIS.
Study NCT05667298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)
Description: Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible.
Study NCT05667298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Description: Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible.
Study NCT04467827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: examining group
Description: Posture assessment in young healthy people depending on their level of physical activity
Study NCT05391607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperoncotic Albumin 20%
Description: Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Study NCT05391607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isooncotic Albumin 5%
Description: Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Study NCT05391607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate Crystalloid Solutions (control group)
Description: Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Study NCT06337344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin
Description: The treatment group will individually perform single-session Baduanjin by following a video broadcasted the standardised BDJ protocol, which lasted for 12 minutes including 6 times of BDJ movements. Breathing rhythm is emphasised to be followed by participants.
Study NCT06337344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The active control group will individually perform 8-sets of aerobic exercise movement by following a video selected by registered physiotherapist.
Study NCT06337344 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Video Viewing
Description: The control group will individually watch a 12-minute video with 6-minute introducing BDJ practice and 6 minute introducing aerobic exercise. This control group is used for controlling the effect of behavioural movement and brain activity generated by passive video viewing.
Study NCT06124326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Premenstrual Syndrome Supplement
Description: Ginger, Curcumin, Organic Turmeric, Black Pepper, Magnesium, Zinc, Vitamin B6, Vitamin D.
Study NCT06502730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creating Opportunities for Parent Empowerment (COPE) Program
Description: It helps to recognize the critical role of parents and encourage taking an active role in their neonate's care, engaging in dyadic interaction with their neonate. COPE program consists of two types of educational information; as teaching parents about normal physical, developmental and behavioral characteristics of their preterm infants and the best ways to interact with them and facilitate their development.
Study NCT04257058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic educational material
Description: Electronic media via email
Study NCT04466371 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
Study NCT06420726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Supervised resistance exercise
Study NCT06420726 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise
Description: Supervised resistance exercise
Study NCT05385510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M™
Description: Adjuvanted malaria vaccine
Study NCT00931905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathic medication Plumbum metallicum
Description: The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
Study NCT00931905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydroalcoholic solution
Description: The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
Study NCT06171165 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Swallow Protocol
Description: All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status.
Study NCT04965597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04965597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04703465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: Tenofovir Alafenamide 25mg for 48 weeks will be delivered
Study NCT04965597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT04965597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT04965597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration
Study NCT04965597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04965597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-ray
Study NCT04965597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo chest CT
Study NCT05647395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracheal tube cuffs differ in deflation
Description: When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
Study NCT06067191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV299
Description: Oral Suspension
Study NCT06067191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT05925478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ptergyopalatine Fossa Block
Description: Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
Study NCT05925478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
Study NCT06566092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145/LN-144
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
Study NCT05455593 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water aerobics
Description: 1-hour session of water aerobics per week, for 3 months. A specialized trainer will carry out water aerobics sessions and will focus on motor coordination, strength and cardiovascular workout.
Study NCT05455593 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Metacognitive Training (MCT)
Description: 1-hour session of MCT per week, for 3 months. A trained psychologist will carry out the MCT sessions. MCT addresses the most common cognitive biases in psychosis. Each session will focus on one topic, such as attributional style, jumping to conclusions, theory of mind, emotion recognition, memory or empathy.
Study NCT05455593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined intervention
Description: Patients in this arm will participate in both in water aerobics and MCT sessions, once a week for each intervention.
Study NCT05858515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG
Description: Nonproprietary name: Baricitinib
Study NCT05858515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04938102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: Injection of 100 units of botulinum toxin into the lower esophageal sphincter (25 units in each quadrant).
Study NCT05117294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral
Study NCT05289505 — intervention group
Intervention type: DEVICE
Intervention: MUSIC-CARE
Description: This device allows the listening of music using different sequences of instrumental music created specifically, and using principles based on hypno-analgesia, that is to say the association of hypnotic techniques and approaches to help or analgesic, medicated or not. It consists of a tablet application containing instrumental music pieces, specially created and recorded for Music-Care. Each piece is at least 20 minutes long. The music can be played through headphones or speakers.
Study NCT05092789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping group
Description: Participants in this group will receive treatment through standardised therapeutic kinesio taping along with conventional therapy.~Tape will place over the posterior cervical extensor muscle, from insertion to the origin, with the patient's neck in cervical contralateral side-bending and rotation.~Duration of kinesio tape will be of 48 hours with 50-100% tension.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions.
Study NCT05092789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical thrust manipulation group
Description: Participants of this group will receive treatment via cervical thrust manipulation along with conventional therapy.~For mid cervical spine thrust manipulation, the patient will be in supine lying position,with cervical spine in neutral position.~The therapist will cradle the patients head with the other hand. Gentle ipsilateral cervical side flexion and contralateral rotation will introduce until tension will perceive in target tissues at contact point. A high velocity, low amplitude thrust manipulation, will direct upward and medially in direction of subject's contralateral eye.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This intervention protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions with 1 month follow up.
Study NCT05092789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy group
Description: Participants of this group will receive only conventional therapy which will include:~Hot pack for 10 minutes Stretching Exercises of neck muscles. For sternocleidomastoid stretching, the subject will ask to sit or stand facing forward, exhale and slowly turn your head to right, by keeping shoulder relaxed and down,inhale and return to the center, then turn to look at your left shoulder, ask to hold this position for 30 seconds and do 3 repetitions.~For Trapezius stretching, patient is seated upright, therapist then passively move right ear to right shoulder.~This study includes interventional protocol of 6 weeks. The session will be given twice a week making it a total of 12 sessions with 1 month follow up.
Study NCT05662371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nociception Level monitor (NOL)
Description: NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuously monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics, and avoiding overdose or underuse of these drugs. The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation).
Study NCT05662371 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Hemodynamic changes outside of the normal range i.e., hypertension (systolic blood pressure greater than 140 mm Hg), tachycardia (heart rate greater than 90 min-1) and hypotension (mean arterial pressure less than 60 mm Hg) will be first assessed using the guidance of Bispectral index and Train of four monitors. Sufentanil in doses of 2.5 to 5 mcg (maximum of 0.6-1.2 mic/kg for the entire surgery) is administered if the Bispectral index and Train of four monitor values are within normal range and if required vasopressor infusion is used. Vasoconstrictors may be given as a continuous infusion of norepinephrine, or bolus doses of ephedrine or phenylephrine. Only when blood pressure remains, low additional crystalloids will be given. Finally, in case of bradycardia (heart rate less than 30 min-1), atropine may be given
Study NCT05059613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotics
Description: one times a day during the whole treatment
Study NCT04760899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
Study NCT04760899 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
Study NCT05011838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1. Health Services Redesign
Description: 1.1. Healthy Hearts service: a nursing station providing blood pressure measurement, cardiovascular risk assessment, preventive counselling and effective follow-up in extended opening hours.~1.2. Hypertension screening: All adults attending health care facilities who did not have their blood pressure measured in the previous year will be referred to the Healthy Hearts Service for screening.~1.3. Clinical management: 1.3.1. Creation of the cardiovascular risk team: a group of doctors supervising hypertension management and coordinating improvement.~1.3.2. Guideline-based standardized diagnostic and treatment protocols: a simplified diagnostic and treatment algorithm will identify a core set of primary and secondary antihypertensive medications.~1.3.3. Availability of antihypertensive medications: it will be assured through procurement mechanisms and its availability will be communicated to clinicians at the beginning of each week and ad hoc in case of stock-outs.
Study NCT05011838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2. Clinical Staff Training
Description: 2.1. Training on good clinical management of hypertension: focused on correct blood pressure measurement, use of evidence-based guidelines, cardiovascular risk assessment, use of a standardized diagnostic and treatment algorithm, correct prescription of pharmacological and non-pharmacological treatment, patient counselling, and how to tackle clinical inertia.~2.2. Training on communication skills and patients' needs assessment for all health workers involved in hypertension care. This training will be designed under the patient-centred medicine framework, aiming at equipping health providers with tools for understanding patients' feelings and experience of illness, and to improve their capacity to address social, psychological, and behavioural dimensions of hypertension care.
Study NCT05011838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3. Patient and Community Engagement
Description: 3.1. Patient empowerment: expert hypertensive patients , under the supervision of a social worker, will provide support and transmit their know-how to other patients in need, particularly those newly diagnosed or non-adherent to treatment or presenting uncontrolled hypertension.~3.2. Community engagement: a Community Hypertension Outreach Group will be set up, composed of existing voluntary community health workers, who will be trained and certified. This group will conduct blood pressure measurements in selected public areas of the commune, referring those with positive screening to the nearest health facility for diagnosis confirmation. It will also provide health information with emphasis on healthy lifestyles. Existing local communication channels such as the community radio and the local newspaper will be engaged.
Study NCT06114576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice enriched with vitamin D3 and encapsulated probiotics
Description: 25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10\^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.
Study NCT06114576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orange juice
Description: 25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.
Study NCT06580041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: CAU plan modified to include a trial of pramipexole.
Study NCT06580041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
Study NCT06580041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenelzine
Description: CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
Study NCT04744025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfluidics chamber
Description: Unwashed sperm will be placed into the inlet chamber of the microfluidics device. The most motile sperm will swim to the outlet chamber, and these sperms will be used for intracytoplasmic sperm injection (ICSI) into the eggs.
Study NCT04744025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Density Gradient Centrifugation
Description: Sperm will be washed and centrifuged according to standard protocol, and these washed sperm will be used for ICSI.